The valine 617 phenylalanine (V617F) mutation in the gene encoding Janus kinase 2 (JAK2) is detected in ~95% of patients with PV and 50–70% of patients with ET (11–13). This evidence concerns the gene JAK2 and essential thrombocythemia.